Fibrinolytic activity is highly influenced by long-term glycemic control in Type 1 diabetic patients [2]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 3, 2006, Pages 686-688

  Seljeflot, Ingebjørg ^a   Larseb, J R ^a   Dahl Jorgensen K ^a   Hanssen, K F ^b   Arnesen, H ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE;

BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FIBRINOLYSIS; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LETTER; LONG TERM CARE; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 33645974275     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01803.x     Document Type: Letter

References (17)

1. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23.000 patients with insulin-treated diabetes. Diabetologia 2003; 46: 760-5.
2. Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jørgensen K. Silent coronary atheromatosis in type-1 diabetic patients and relation to long-term glycemic control. Diabetes 2002; 51: 2637-41.
3. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type-1 diabetes without nephropathy. Arteroscler Thromb Vasc Biol 1999; 19: 1014-9.
4. Dahl-Jørgensen K, Brinchmann-Hansen O, Hansen KF, Ganes T, Kierulf P, Smeland E, Sandvik L, Aagenes O. Effects of near normoglycemia for two years on progression of early diabetes retinopathy, nephropathy, and neuropathy: The Oslo study. BMJ 1986; 293: 1195-9.
5. The Diabetes Control and Complications Trial Research Group. The effects of intensive insulin treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-86.
6. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arteroscler Thromb 1993; 13: 1865-73.
7. Wieczorek I, Pell ACH, McIver B, MacGregor IR. Coagulation and fibrinolytic systems in type 1 diabetes: Effects of venous occlusion and insulin-induced hypoglycaemia. Clin Sci 1993; 84: 79-86.
8. Hilberg T, Eichler E, Gläser D, Prasa D, Stürzebecher J, Gabriel HHW. Blood coagulation and fibrinolysis before and after exhaustive exercise in patients with IDDM. Thromb Haemost 2003; 90: 1065-73.
9. Seljeflot I, Arnesen H, Eritsland J, Smith P. D-dimer test after standardized coagulation. A new assay for evaluation of the unstimulated fibrinolytic system. Fibrinolysis 1993; 7: 303-7.
10. 1c: A comparison with ion-exchange chromatography. Scand J Clin Lab Invest 1982; 42: 27-33.
11. Ahmed N. Advanced glycation endproducts -role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21.
12. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Metab Care 2002; 5: 561-8.
13. Uchida Y, Ohba K, Yoshioka T, Irie K, Muraki T, Maru Y. Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathways. J Biol Chem 2004; 279: 4075-83.
14. Nielsen VG, Crow JP, Zhou F, Parks DA. Peroxynitrite inactivates tissue plasminogen activator. Anesth Analg 2004; 98: 1312-7.
15. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: Implication for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-92.
16. Hansen TK, Thiel S, Knudsen ST, Gravholt CH, Christiansen JS, Mogensen CE, Poulsen PL. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 4857-61.
17. Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, Eisenbarth GS, Rewers M. Elevated C-reactive protein levels in the development of type 2 diabetes. Diabetes 2004; 53: 2569-73.